SCHEMBL16446545

SCHEMBL16446545

COC(=O)CCSc1c[nH]c2nc(-c3ccc(OC)c(F)c3)nc(C)c12

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.36
▸ AR P10275 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ ADORA3 P0DMS8 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ PDE4D Q08499 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ STK17B O94768 1/20 0.34
▸ ROCK2 O75116 1/20 0.34
▸ PDGFRB P09619 1/20 0.33
▸ PDGFRA P16234 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19118470 0.84 PDE4B (0.36) PDE4BARMAPTL3MBTL1ALDH1A1
SCHEMBL16446457 0.76 TRPA1 (0.42) MAPTL3MBTL1ALDH1A1NPC1MEN1
SCHEMBL16446732 0.74 NR3C1 (0.44) PDE4BMAPTALDH1A1NPC1MEN1
SCHEMBL16446763 0.72 PDE4B (0.45) PDE4BMAPTALDH1A1MEN1KMT2A
SCHEMBL16447032 0.70 DCTPP1 (0.47) PDE4BL3MBTL1ALDH1A1PDE4DRAB9A
SCHEMBL16446403 0.69 DCTPP1 (0.46) PDE4BL3MBTL1MEN1KMT2APDE4D
SCHEMBL16447012 0.68 ALDH1A1 (0.44) MAPTL3MBTL1ALDH1A1NPC1MEN1
SCHEMBL16446133 0.65 GAA (0.51) PDE4BMAPTALDH1A1PDE4DRAB9A
SCHEMBL23406153 0.64 TDP1 (0.46) MAPTNPC1MEN1KMT2ARAB9A
SCHEMBL13518572 0.62 GSTP1 (0.40) MAPTALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885AR 3413/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback